Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer.
Schrader
Andres J
AJ
Department of Urology, Philipps-University Medical School, Marburg, Germany. ajschrader@gmx.de
Varga
Zoltan
Z
Pfoertner
Susanne
S
Goelden
Ulrike
U
Buer
Jan
J
Hofmann
Rainer
R
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D013792:Thalidomide / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D013792:Thalidomide